Innoviva, Inc. (INVA)
21.03
-0.04
(-0.19%)
USD |
NASDAQ |
Aug 24, 16:00
21.03
0.00 (0.00%)
After-Hours: 20:00
Innoviva Enterprise Value : 1.218B for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 1.218B |
| August 21, 2026 | 1.221B |
| August 20, 2026 | 1.216B |
| August 19, 2026 | 1.251B |
| August 18, 2026 | 1.234B |
| August 17, 2026 | 1.213B |
| August 14, 2026 | 1.230B |
| August 13, 2026 | 1.198B |
| August 12, 2026 | 1.202B |
| August 11, 2026 | 1.198B |
| August 10, 2026 | 1.193B |
| August 07, 2026 | 1.180B |
| August 06, 2026 | 1.224B |
| August 05, 2026 | 1.180B |
| August 04, 2026 | 1.206B |
| August 03, 2026 | 1.199B |
| July 31, 2026 | 1.214B |
| July 30, 2026 | 1.232B |
| July 29, 2026 | 1.262B |
| July 28, 2026 | 1.275B |
| July 27, 2026 | 1.238B |
| July 24, 2026 | 1.248B |
| July 23, 2026 | 1.231B |
| July 22, 2026 | 1.247B |
| July 21, 2026 | 1.258B |
| Date | Value |
|---|---|
| July 20, 2026 | 1.236B |
| July 17, 2026 | 1.268B |
| July 16, 2026 | 1.304B |
| July 15, 2026 | 1.281B |
| July 14, 2026 | 1.270B |
| July 13, 2026 | 1.304B |
| July 10, 2026 | 1.306B |
| July 09, 2026 | 1.303B |
| July 08, 2026 | 1.320B |
| July 07, 2026 | 1.307B |
| July 06, 2026 | 1.276B |
| July 02, 2026 | 1.311B |
| July 01, 2026 | 1.281B |
| June 30, 2026 | 1.340B |
| June 29, 2026 | 1.423B |
| June 26, 2026 | 1.454B |
| June 25, 2026 | 1.438B |
| June 24, 2026 | 1.460B |
| June 23, 2026 | 1.453B |
| June 22, 2026 | 1.388B |
| June 18, 2026 | 1.375B |
| June 17, 2026 | 1.386B |
| June 16, 2026 | 1.384B |
| June 15, 2026 | 1.370B |
| June 12, 2026 | 1.393B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Zevra Therapeutics, Inc. | 471.26M |
| Collegium Pharmaceutical, Inc. | 1.957B |
| CorMedix, Inc. | 530.88M |
| ANI Pharmaceuticals, Inc. | 1.938B |
| Corcept Therapeutics, Inc. | 13.00B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -83.42M |
| Revenue (Quarterly) | 123.05M |
| Total Expenses (Quarterly) | 206.47M |
| EPS Diluted (Quarterly) | -1.136 |
| Gross Profit Margin (Quarterly) | 73.64% |
| Profit Margin (Quarterly) | -67.80% |
| Earnings Yield | 19.52% |
| Operating Earnings Yield | 9.41% |
| Normalized Earnings Yield | 10.87 |